Recent advances have revealed that afatinib, the second-generation TKIs approved for first-line treatment of NSCLC, shows clinical activity against many rare EGFR mutations, especially for highly detectable G719X, L861G, and S768I mutations (Yang et al., 2015; Yang et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.